Simvastatin 10 mg tablets, packaged in a) 30-count bottles (NDC 70518-0064-01) and b) 90-count bo...

FDA Drug Recall #D-0496-2023 — Class II — March 20, 2023

Recall Summary

Recall Number D-0496-2023
Classification Class II — Moderate risk
Date Initiated March 20, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm RemedyRepack Inc.
Location Indiana, PA
Product Type Drugs
Quantity a) 1,262 bottles, b) 95 bottles

Product Description

Simvastatin 10 mg tablets, packaged in a) 30-count bottles (NDC 70518-0064-01) and b) 90-count bottles (NDC 70518-0064-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701

Reason for Recall

cGMP Deviations

Distribution Pattern

RemedyRepack distributed product to consignees nationwide within the United States

Lot / Code Information

Lot #: a) J0675206-011223, J0669260-121922, Exp. Date 01/31/2024; J0656820-103122, J0647161-091722, Exp. Date 09/30/2023 Exp. Date 11/30/2023; J0621491-052722, Exp. Date 06/30/2023; J0638138-080822, Exp. Date 08/31/2023, J0610887-041122, Exp. Date 04/30/2023. Lot # b) B1887315-100422, Exp. Date 02/28/2024; B1829906-083122, B1769715-071622, Exp. Date 09/30/2023; B1906605-101422, Exp. Date 02/28/2024; B1965118-111622, Exp. Date 02/28/2025.

Other Recalls from RemedyRepack Inc.

Recall # Classification Product Date
D-0411-2025 Class II Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsul... Apr 22, 2025
D-0378-2025 Class II Clindamycin HCl, 300 mg Capsule, QTY: 30 Capsul... Mar 24, 2025
D-0217-2025 Class II Carvedilol 25 mg Tablet, QTY: 30 Tablets per Bl... Jan 24, 2025
D-0165-2025 Class II Duloxetine Delayed-Release Capsules, 60 mg, a) ... Dec 2, 2024
D-0611-2024 Class II Potassium Chloride Micro 10mEq K (750 mg) Exten... Jun 26, 2024

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.